Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

Rye KA.

Clin Exp Nephrol. 2014 Apr;18(2):247-50. doi: 10.1007/s10157-013-0865-x. Epub 2013 Sep 20. Review.

PMID:
24052156
4.

Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I.

Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12224-9. doi: 10.1073/pnas.0802025105. Epub 2008 Aug 21.

5.

Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.

Zannis VI, Chroni A, Krieger M.

J Mol Med (Berl). 2006 Apr;84(4):276-94. Epub 2006 Feb 25. Review.

PMID:
16501936
6.

Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.

Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomäki A, Miettinen TA, Kontula K.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3021-32.

7.
8.

The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA.

Diabetologia. 2007 Mar;50(3):643-53. Epub 2007 Jan 10.

PMID:
17216278
10.

Discoidal complexes containing apolipoprotein E and their transformation by lecithin-cholesterol acyltransferase.

Gong EL, Nichols AV, Weisgraber KH, Forte TM, Shore VG, Blanche PJ.

Biochim Biophys Acta. 1989 Dec 18;1006(3):317-28.

PMID:
2597674
11.

Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells.

Ohnsorg PM, Mary JL, Rohrer L, Pech M, Fingerle J, von Eckardstein A.

Biochim Biophys Acta. 2011 Dec;1811(12):1115-23. doi: 10.1016/j.bbalip.2011.09.001. Epub 2011 Sep 10.

PMID:
21930241
12.
13.
14.

Effect of the cholesterol content of reconstituted LpA-I on lecithin:cholesterol acyltransferase activity.

Sparks DL, Anantharamaiah GM, Segrest JP, Phillips MC.

J Biol Chem. 1995 Mar 10;270(10):5151-7.

15.
16.

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

Chen X, Burton C, Song X, McNamara L, Langella A, Cianetti S, Chang CH, Wang J.

Int J Biol Sci. 2009 Jul 28;5(5):489-99.

17.

Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles.

Sparks DL, Frank PG, Braschi S, Neville TA, Marcel YL.

Biochemistry. 1999 Feb 9;38(6):1727-35.

PMID:
10026251
18.

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.

Gille A, Easton R, D'Andrea D, Wright SD, Shear CL.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2106-14. doi: 10.1161/ATVBAHA.114.303720. Epub 2014 Jun 26.

19.

Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding.

Minnich A, Collet X, Roghani A, Cladaras C, Hamilton RL, Fielding CJ, Zannis VI.

J Biol Chem. 1992 Aug 15;267(23):16553-60.

20.

LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.

Koukos G, Chroni A, Duka A, Kardassis D, Zannis VI.

Biochemistry. 2007 Sep 18;46(37):10713-21. Epub 2007 Aug 21.

PMID:
17711302
Items per page

Supplemental Content

Write to the Help Desk